APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Hyperimmune Globulins

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Hyperimmune Globulins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173999830327 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Hyperimmune Globulins Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Hyperimmune Globulins Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Human Hyperimmune Globulins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Hyperimmune Globulins Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Hyperimmune Globulins Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Human Hyperimmune Globulins market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human Hyperimmune Globulins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Hyperimmune Globulins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Hyperimmune Globulins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Hyperimmune Globulins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Hyperimmune Globulins include CNBG, Sichuan Yuanda Shuyang, Shanghai RAAS, Hualan Bio, CBPO, Kedrion, Kamada, Grifols and Emergent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Hyperimmune Globulins market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Hyperimmune Globulins and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Hyperimmune Globulins sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Hyperimmune Globulins market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Hyperimmune Globulins Segment by Company

CNBG

Sichuan Yuanda Shuyang

Shanghai RAAS

Hualan Bio

CBPO

Kedrion

Kamada

Grifols

Emergent

CSL Behring

Biotest

ADMA Biologics

Human Hyperimmune Globulins Segment by Type

Varicella-Zoster Immune Globulin

Cytomegalovirus Immune Globulin

Rho(D) Immune Globulin

Rabies Immuneglobulins

Tetanus Toxin Immuneglobulins

Hepatitis B Immuneglobulins

Others

Human Hyperimmune Globulins Segment by Application

Government Institutions

Private Sector

Others

Human Hyperimmune Globulins Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Hyperimmune Globulins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Hyperimmune Globulins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Hyperimmune Globulins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Hyperimmune Globulins market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Hyperimmune Globulins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Hyperimmune Globulins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Hyperimmune Globulins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Hyperimmune Globulins Industry Trends Table 2. Human Hyperimmune Globulins Industry Drivers Table 3. Human Hyperimmune Globulins Industry Opportunities and Challenges Table 4. Human Hyperimmune Globulins Industry Restraints Table 5. Global Human Hyperimmune Globulins Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Hyperimmune Globulins Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Hyperimmune Globulins Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Human Hyperimmune Globulins Sales Market Share by Manufacturers Table 9. Global Human Hyperimmune Globulins Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Human Hyperimmune Globulins Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Hyperimmune Globulins Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Hyperimmune Globulins Manufacturers, Product Type & Application Table 13. Global Human Hyperimmune Globulins Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Hyperimmune Globulins by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Varicella-Zoster Immune Globulin Table 17. Major Manufacturers of Cytomegalovirus Immune Globulin Table 18. Major Manufacturers of Rho(D) Immune Globulin Table 19. Major Manufacturers of Rabies Immuneglobulins Table 20. Major Manufacturers of Tetanus Toxin Immuneglobulins Table 21. Major Manufacturers of Hepatitis B Immuneglobulins Table 22. Major Manufacturers of Others Table 23. Global Human Hyperimmune Globulins Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Human Hyperimmune Globulins Sales by Type (2021-2026) & (K Units) Table 25. Global Human Hyperimmune Globulins Sales by Type (2027-2032) & (K Units) Table 26. Global Human Hyperimmune Globulins Sales Market Share by Type (2021-2026) Table 27. Global Human Hyperimmune Globulins Sales Market Share by Type (2027-2032) Table 28. Global Human Hyperimmune Globulins Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global Human Hyperimmune Globulins Revenue by Type (2021-2026) & (K Units) Table 30. Global Human Hyperimmune Globulins Revenue by Type (2027-2032) & (K Units) Table 31. Global Human Hyperimmune Globulins Revenue Market Share by Type (2021-2026) Table 32. Global Human Hyperimmune Globulins Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Government Institutions Table 34. Major Manufacturers of Private Sector Table 35. Major Manufacturers of Others Table 36. Global Human Hyperimmune Globulins Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Human Hyperimmune Globulins Sales by Application (2021-2026) & (K Units) Table 38. Global Human Hyperimmune Globulins Sales by Application (2027-2032) & (K Units) Table 39. Global Human Hyperimmune Globulins Sales Market Share by Application (2021-2026) Table 40. Global Human Hyperimmune Globulins Sales Market Share by Application (2027-2032) Table 41. Global Human Hyperimmune Globulins Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Human Hyperimmune Globulins Revenue by Application (2021-2026) & (K Units) Table 43. Global Human Hyperimmune Globulins Revenue by Application (2027-2032) & (K Units) Table 44. Global Human Hyperimmune Globulins Revenue Market Share by Application (2021-2026) Table 45. Global Human Hyperimmune Globulins Revenue Market Share by Application (2027-2032) Table 46. Global Human Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Human Hyperimmune Globulins Sales by Region (2021-2026) & (K Units) Table 48. Global Human Hyperimmune Globulins Sales Market Share by Region (2021-2026) Table 49. Global Human Hyperimmune Globulins Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Human Hyperimmune Globulins Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Human Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 53. North America Human Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 54. Europe Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Human Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 56. Europe Human Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Human Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Human Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Human Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Human Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 63. Global Human Hyperimmune Globulins Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Human Hyperimmune Globulins Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Human Hyperimmune Globulins Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Human Hyperimmune Globulins Revenue Market Share by Region (2021-2026) Table 67. Global Human Hyperimmune Globulins Revenue Market Share by Region (2027-2032) Table 68. CNBG Company Information Table 69. CNBG Business Overview Table 70. CNBG Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CNBG Human Hyperimmune Globulins Product Portfolio Table 72. CNBG Recent Development Table 73. Sichuan Yuanda Shuyang Company Information Table 74. Sichuan Yuanda Shuyang Business Overview Table 75. Sichuan Yuanda Shuyang Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sichuan Yuanda Shuyang Human Hyperimmune Globulins Product Portfolio Table 77. Sichuan Yuanda Shuyang Recent Development Table 78. Shanghai RAAS Company Information Table 79. Shanghai RAAS Business Overview Table 80. Shanghai RAAS Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Shanghai RAAS Human Hyperimmune Globulins Product Portfolio Table 82. Shanghai RAAS Recent Development Table 83. Hualan Bio Company Information Table 84. Hualan Bio Business Overview Table 85. Hualan Bio Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Hualan Bio Human Hyperimmune Globulins Product Portfolio Table 87. Hualan Bio Recent Development Table 88. CBPO Company Information Table 89. CBPO Business Overview Table 90. CBPO Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. CBPO Human Hyperimmune Globulins Product Portfolio Table 92. CBPO Recent Development Table 93. Kedrion Company Information Table 94. Kedrion Business Overview Table 95. Kedrion Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Kedrion Human Hyperimmune Globulins Product Portfolio Table 97. Kedrion Recent Development Table 98. Kamada Company Information Table 99. Kamada Business Overview Table 100. Kamada Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Kamada Human Hyperimmune Globulins Product Portfolio Table 102. Kamada Recent Development Table 103. Grifols Company Information Table 104. Grifols Business Overview Table 105. Grifols Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Grifols Human Hyperimmune Globulins Product Portfolio Table 107. Grifols Recent Development Table 108. Emergent Company Information Table 109. Emergent Business Overview Table 110. Emergent Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Emergent Human Hyperimmune Globulins Product Portfolio Table 112. Emergent Recent Development Table 113. CSL Behring Company Information Table 114. CSL Behring Business Overview Table 115. CSL Behring Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. CSL Behring Human Hyperimmune Globulins Product Portfolio Table 117. CSL Behring Recent Development Table 118. Biotest Company Information Table 119. Biotest Business Overview Table 120. Biotest Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Biotest Human Hyperimmune Globulins Product Portfolio Table 122. Biotest Recent Development Table 123. ADMA Biologics Company Information Table 124. ADMA Biologics Business Overview Table 125. ADMA Biologics Human Hyperimmune Globulins Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. ADMA Biologics Human Hyperimmune Globulins Product Portfolio Table 127. ADMA Biologics Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Human Hyperimmune Globulins Distributors List Table 131. Human Hyperimmune Globulins Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Human Hyperimmune Globulins Product Image Figure 2. Global Human Hyperimmune Globulins Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Hyperimmune Globulins Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Hyperimmune Globulins Sales (2021-2032) & (K Units) Figure 5. Global Human Hyperimmune Globulins Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Hyperimmune Globulins Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Varicella-Zoster Immune Globulin Image Figure 9. Cytomegalovirus Immune Globulin Image Figure 10. Rho(D) Immune Globulin Image Figure 11. Rabies Immuneglobulins Image Figure 12. Tetanus Toxin Immuneglobulins Image Figure 13. Hepatitis B Immuneglobulins Image Figure 14. Others Image Figure 15. Global Human Hyperimmune Globulins Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Human Hyperimmune Globulins Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Human Hyperimmune Globulins Sales Market Share by Type (2021-2032) Figure 18. Global Human Hyperimmune Globulins Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Human Hyperimmune Globulins Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human Hyperimmune Globulins Revenue Market Share by Type (2021-2032) Figure 21. Government Institutions Image Figure 22. Private Sector Image Figure 23. Others Image Figure 24. Global Human Hyperimmune Globulins Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Human Hyperimmune Globulins Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Human Hyperimmune Globulins Sales Market Share by Application (2021-2032) Figure 27. Global Human Hyperimmune Globulins Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Human Hyperimmune Globulins Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Human Hyperimmune Globulins Revenue Market Share by Application (2021-2032) Figure 30. North America Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Human Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 32. U.S. Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Human Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 37. Germany Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Human Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 44. China Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Human Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 52. Brazil Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Human Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Human Hyperimmune Globulins Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Human Hyperimmune Globulins Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Human Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 63. North America Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Human Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 65. Europe Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Human Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Human Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Human Hyperimmune Globulins Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Human Hyperimmune Globulins Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella-Zoster Immune Globulin
  • Cytomegalovirus Immune Globulin
  • Rho(D) Immune Globulin
  • Rabies Immuneglobulins
  • Tetanus Toxin Immuneglobulins
  • Hepatitis B Immuneglobulins
  • Others
Applications
  • Government Institutions
  • Private Sector
  • Others
Companies covered
  • CNBG
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Hualan Bio
  • CBPO
  • Kedrion
  • Kamada
  • Grifols
  • Emergent
  • CSL Behring
  • Biotest
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Hyperimmune Globulins Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Hyperimmune Globulins Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Hyperimmune Globulins Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Hyperimmune Globulins Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Hyperimmune Globulins Market Dynamics
  1. 2.1 Human Hyperimmune Globulins Industry Trends
  2. 2.2 Human Hyperimmune Globulins Industry Drivers
  3. 2.3 Human Hyperimmune Globulins Industry Opportunities and Challenges
  4. 2.4 Human Hyperimmune Globulins Industry Restraints
3 Human Hyperimmune Globulins Market by Manufacturers
  1. 3.1 Global Human Hyperimmune Globulins Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Hyperimmune Globulins Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Hyperimmune Globulins Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Hyperimmune Globulins Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Hyperimmune Globulins Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Hyperimmune Globulins Manufacturers, Product Type & Application
  7. 3.7 Global Human Hyperimmune Globulins Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Hyperimmune Globulins Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Hyperimmune Globulins Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Hyperimmune Globulins Tier 1, Tier 2, and Tier 3
4 Human Hyperimmune Globulins Market by Type
  1. 4.1 Human Hyperimmune Globulins Type Introduction
  2. 4.1.1 Varicella-Zoster Immune Globulin
  3. 4.1.2 Cytomegalovirus Immune Globulin
  4. 4.1.3 Rho(D) Immune Globulin
  5. 4.1.4 Rabies Immuneglobulins
  6. 4.1.5 Tetanus Toxin Immuneglobulins
  7. 4.1.6 Hepatitis B Immuneglobulins
  8. 4.1.7 Others
  9. 4.2 Global Human Hyperimmune Globulins Sales by Type
  10. 4.2.1 Global Human Hyperimmune Globulins Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Human Hyperimmune Globulins Sales by Type (2021-2032)
  12. 4.2.3 Global Human Hyperimmune Globulins Sales Market Share by Type (2021-2032)
  13. 4.3 Global Human Hyperimmune Globulins Revenue by Type
  14. 4.3.1 Global Human Hyperimmune Globulins Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Human Hyperimmune Globulins Revenue by Type (2021-2032)
  16. 4.3.3 Global Human Hyperimmune Globulins Revenue Market Share by Type (2021-2032)
5 Human Hyperimmune Globulins Market by Application
  1. 5.1 Human Hyperimmune Globulins Application Introduction
  2. 5.1.1 Government Institutions
  3. 5.1.2 Private Sector
  4. 5.1.3 Others
  5. 5.2 Global Human Hyperimmune Globulins Sales by Application
  6. 5.2.1 Global Human Hyperimmune Globulins Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Hyperimmune Globulins Sales by Application (2021-2032)
  8. 5.2.3 Global Human Hyperimmune Globulins Sales Market Share by Application (2021-2032)
  9. 5.3 Global Human Hyperimmune Globulins Revenue by Application
  10. 5.3.1 Global Human Hyperimmune Globulins Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Hyperimmune Globulins Revenue by Application (2021-2032)
  12. 5.3.3 Global Human Hyperimmune Globulins Revenue Market Share by Application (2021-2032)
6 Global Human Hyperimmune Globulins Sales by Region
  1. 6.1 Global Human Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Hyperimmune Globulins Sales by Region (2021-2032)
  3. 6.2.1 Global Human Hyperimmune Globulins Sales by Region (2021-2026)
  4. 6.2.2 Global Human Hyperimmune Globulins Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Hyperimmune Globulins Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Hyperimmune Globulins Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Hyperimmune Globulins Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Hyperimmune Globulins Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Hyperimmune Globulins Revenue by Region
  1. 7.1 Global Human Hyperimmune Globulins Revenue by Region
  2. 7.1.1 Global Human Hyperimmune Globulins Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Hyperimmune Globulins Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Hyperimmune Globulins Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Hyperimmune Globulins Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Hyperimmune Globulins Revenue (2021-2032)
  8. 7.2.2 North America Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Hyperimmune Globulins Revenue (2021-2032)
  11. 7.3.2 Europe Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Hyperimmune Globulins Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Hyperimmune Globulins Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CNBG
  2. 8.1.1 CNBG Company Information
  3. 8.1.2 CNBG Business Overview
  4. 8.1.3 CNBG Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CNBG Human Hyperimmune Globulins Product Portfolio
  6. 8.1.5 CNBG Recent Developments
  7. 8.2 Sichuan Yuanda Shuyang
  8. 8.2.1 Sichuan Yuanda Shuyang Company Information
  9. 8.2.2 Sichuan Yuanda Shuyang Business Overview
  10. 8.2.3 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Product Portfolio
  12. 8.2.5 Sichuan Yuanda Shuyang Recent Developments
  13. 8.3 Shanghai RAAS
  14. 8.3.1 Shanghai RAAS Company Information
  15. 8.3.2 Shanghai RAAS Business Overview
  16. 8.3.3 Shanghai RAAS Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai RAAS Human Hyperimmune Globulins Product Portfolio
  18. 8.3.5 Shanghai RAAS Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Human Hyperimmune Globulins Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 CBPO
  26. 8.5.1 CBPO Company Information
  27. 8.5.2 CBPO Business Overview
  28. 8.5.3 CBPO Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CBPO Human Hyperimmune Globulins Product Portfolio
  30. 8.5.5 CBPO Recent Developments
  31. 8.6 Kedrion
  32. 8.6.1 Kedrion Company Information
  33. 8.6.2 Kedrion Business Overview
  34. 8.6.3 Kedrion Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kedrion Human Hyperimmune Globulins Product Portfolio
  36. 8.6.5 Kedrion Recent Developments
  37. 8.7 Kamada
  38. 8.7.1 Kamada Company Information
  39. 8.7.2 Kamada Business Overview
  40. 8.7.3 Kamada Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Kamada Human Hyperimmune Globulins Product Portfolio
  42. 8.7.5 Kamada Recent Developments
  43. 8.8 Grifols
  44. 8.8.1 Grifols Company Information
  45. 8.8.2 Grifols Business Overview
  46. 8.8.3 Grifols Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Grifols Human Hyperimmune Globulins Product Portfolio
  48. 8.8.5 Grifols Recent Developments
  49. 8.9 Emergent
  50. 8.9.1 Emergent Company Information
  51. 8.9.2 Emergent Business Overview
  52. 8.9.3 Emergent Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Emergent Human Hyperimmune Globulins Product Portfolio
  54. 8.9.5 Emergent Recent Developments
  55. 8.10 CSL Behring
  56. 8.10.1 CSL Behring Company Information
  57. 8.10.2 CSL Behring Business Overview
  58. 8.10.3 CSL Behring Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSL Behring Human Hyperimmune Globulins Product Portfolio
  60. 8.10.5 CSL Behring Recent Developments
  61. 8.11 Biotest
  62. 8.11.1 Biotest Company Information
  63. 8.11.2 Biotest Business Overview
  64. 8.11.3 Biotest Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biotest Human Hyperimmune Globulins Product Portfolio
  66. 8.11.5 Biotest Recent Developments
  67. 8.12 ADMA Biologics
  68. 8.12.1 ADMA Biologics Company Information
  69. 8.12.2 ADMA Biologics Business Overview
  70. 8.12.3 ADMA Biologics Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ADMA Biologics Human Hyperimmune Globulins Product Portfolio
  72. 8.12.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Hyperimmune Globulins Value Chain Analysis
  2. 9.1.1 Human Hyperimmune Globulins Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Hyperimmune Globulins Production Mode & Process
  6. 9.2 Human Hyperimmune Globulins Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Hyperimmune Globulins Distributors
  9. 9.2.3 Human Hyperimmune Globulins Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst